Evaluation of Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution, 0.025% for Treatment of Ocular Redness

References

• Cronau H, Kankanala RR, Mauger T. Diagnosis and management of red eye in primary care. Am Fam Physician. 2010;81(2):137–44.
   PubMed Web of Science ®Google Scholar
• Galor A, Jeng BH. Red eye for the internist: when ot treat, when to refer. Cleve Clin J Med. 2008;75(2):137–44. doi:10.3949/ccjm.75.2.137.
   PubMed Web of Science ®Google Scholar
• Haveles EB. Chapter 4: Autonomic drugs. In: Applied pharmacology for the dental hygienist. 7th ed. Maryland Heights, MO: Elsevier; 2016, p. 44.
   Google Scholar
• Shanbhag T. Pharmacology: Prep manual for undergraduates. India: Elsevier; 2008, p. 73.
   Google Scholar
• Spector SL, Raizman MB. Conjunctivitis medicamentosa. J Allergy Clin Immunol. 1994;94(1):134–36. doi:10.1016/0091-6749(94)90081-7.
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Sarra GM, Abegg M. Abuse of vasoconstrictive eyedrops mimicking an ocular pemphigoid. Eur J Ophthalmol. 2009;19(1):129–32.
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S, Williamson P, Clearie K, Khan F, Kipworth B. Fluticasone reverses oxymetazoline induced tachyphylaxis of response and rebound congestion. Am J Respir Crit Care Med. 2010;182(1):19–24. doi:10.1164/rccm.200911-1701OC.
   PubMed Web of Science ®Google Scholar
• Soparkar CN, Wilhelmus KR, Koch DD, Wallace GW, Jones DB. Acute and chronic conjunctivitis due to over-the-counter ophthalmic decongestants. Arch Ophthalmol. 1997;115(1):34–38. doi:10.1001/archopht.1997.01100150036004.
   PubMedGoogle Scholar
• Fratelli M, De Blasi A. Agonist-induced alpha 1-adrenergic receptor changes. Evidence for receptor sequestration. FEBS Lett. 1987;212(1):149–53. doi:10.1016/0014-5793(87)81575-2.
   PubMed Web of Science ®Google Scholar
• Corboz MR, Rivelli MA, Mingo GG, McLeod RL, Varty L, Jia Y, Hey JA. Mechanism of decongestant activity of alpha-2 agonists. Pulm Pharmacol Ther. 2008;21:449–54. doi:10.1016/j.pupt.2007.06.007.
   PubMed Web of Science ®Google Scholar
• Corboz MR, Mutter JC, Rivelli MA, Mingo GG, McLeod RL, Varty L, Jia Y, Cartwright M, Hey JA. Alpha2-adrenoceptor agonists as nasal decongestants. Pulm Pharmacol Ther. 2007;20(2):149–56. doi:10.1016/j.pupt.2006.03.012.
   PubMed Web of Science ®Google Scholar
• Adkins JC, Balfour JA. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging. 1998;12(3):225–41. doi:10.2165/00002512-199812030-00005.
   PubMed Web of Science ®Google Scholar
• Fudemberg SJ, Batiste C, Katz LJ. Efficacy, safety, and current applications of brimonidine. Expert Opin Drug Saf. 2008;7(6):795–99. doi:10.1517/17425250802457609.
   PubMed Web of Science ®Google Scholar
• Rahman MQ, Ramaesh K, Montgomery DM. Brimonidine for glaucoma. Expert Opin Drug Saf. 2010;9(3):483–91. doi:10.1517/14740331003709736.
   PubMed Web of Science ®Google Scholar
• Fowler J, Jr., Jackson JM, Moore A, Jarratt M, Jones T, Meadows K, Steinhoff M, Rudisill D, Leoni M. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol. 2013;12(6):650–56.
   PubMed Web of Science ®Google Scholar
• Tong LX, Moore AY. Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea. Expert Rev Clin Pharmacol. 2014;7(5):567–77. doi:10.1586/17512433.2014.945910.
   PubMed Web of Science ®Google Scholar
• Dahlmann-Noor AH, Cosgrave E, Lowe S, Bailly M, Vivian AJ. Brimonidine and apraclonidine as vasoconstrictors in adjustable strabismus surgery. J Aapos. 2009;13:123–26. doi:10.1016/j.jaapos.2008.12.001.
   PubMed Web of Science ®Google Scholar
• Gupta A, Kekunnaya R, Sachdeva V, Rao HL. Strabismus surgery hemostasis. Ophthalmology. 2012;119(3):649–50. doi:10.1016/j.ophtha.2011.10.005.
   PubMed Web of Science ®Google Scholar
• Hong S, Kim CY, Seong GJ, Han SH. Effect of prophylactic brimonidine instillation on bleeding during strabismus surgery in adults. Am J Ophthalmol. 2007;144(3):469–70. doi:10.1016/j.ajo.2007.04.038.
   PubMed Web of Science ®Google Scholar
• Desco MC, Navea A, Ferrer E, Menezo JL. Effect of prophylactic brimonidine on bleeding complications after cataract surgery. Eur J Ophthalmol. 2005;15(2):228–32.
   PubMed Web of Science ®Google Scholar
• Pasquali TA, Aufderheide A, Brinton JP, Avila MR, Stahl ED, Durrie DS. Dilute brimonidine to improve patient comfort and subconjunctival hemorrhage after LASIK. J Refract Surg. 2013;29:469–75. doi:10.3928/1081597X-20130617-05.
   PubMed Web of Science ®Google Scholar
• Norden RA. Effect of prophylactic brimonidine on bleeding complications and flap adherence after laser in situ keratomileusis. J Refract Surg. 2002;18:468–71.
   PubMed Web of Science ®Google Scholar
• Kim CS, Nam KY, Kim JY. Effect of prophylactic topical brimonidine (0.15%) administration on the development of subconjunctival hemorrhage after intravitreal injection. Retina. 2011;31(2):389–92. doi:10.1097/IAE.0b013e3181eef28e.
   PubMed Web of Science ®Google Scholar
• Derick RJ, Robin AL, Walters TR, Barnebey HS, Chopin N, Schuman J, Kelley EP, Chen K, Stoecker JF. Brimonidine tartrate: A one month dose response study. Ophthalmology. 1997;104:131–36. doi:10.1016/S0161-6420(97)30349-2.
   PubMed Web of Science ®Google Scholar
• Kim CY, Hong S, Seong GJ. Brimonidine 0.2% versus brimonidine Purite 0.15% in Asian ocular hypertension. J Ocul Pharmacol Ther. 2007;23(5):481–86. doi:10.1089/jop.2007.0042.
   PubMed Web of Science ®Google Scholar
• Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002;11:119–26. doi:10.1097/00061198-200204000-00007.
   PubMed Web of Science ®Google Scholar
• McDonald JE, El-Moatassem Kotb AM, Decker BB. Effect of brimonidine tartrate ophthalmic solution 0.2% on pupil size in normal eyes under different luminance conditions. J Cataract Refract Surg. 2001;27:560–64. doi:10.1016/S0886-3350(01)00769-6.
   PubMed Web of Science ®Google Scholar
• Thordsen JE, Bower KS, Warren BB, Stutzman R. Miotic effect of brimonidine tartrate 0.15% ophthalmic solution in normal eyes. J Cataract Refract Surg. 2004;27:1702–06. doi:10.1016/j.jcrs.2003.12.037.
   Web of Science ®Google Scholar
• Kesler A, Shemesh G, Rothkoff L, Lazar M. Effect of brimonidine tartrate 0.2% ophthalmic solution on pupil size. J Cataract Refract Surg. 2004;30:1707–10. doi:10.1016/j.jcrs.2004.02.043.
   PubMed Web of Science ®Google Scholar
• Katz LJ, Brimonidine Study Group. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Am J Ophthalmol. 1999;127:20–26. doi:10.1016/S0002-9394(98)00286-4.
   PubMed Web of Science ®Google Scholar
• LeBlanc RP. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Ophthalmology. 1998;105:1960–67. doi:10.1016/S0161-6420(98)91048-X.
   PubMed Web of Science ®Google Scholar
• Carollo DS, Nossaman BD, Ramadhyani U. Dexmedetomidine: a review of clinical applications. Curr Opin Anaesthesiol. 2008;21(4):457–61. doi:10.1097/ACO.0b013e328305e3ef.
   PubMed Web of Science ®Google Scholar
• Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol. 1996;41(Suppl 1):S19–26. doi:10.1016/S0039-6257(96)82028-5.
   PubMed Web of Science ®Google Scholar
• Lee D, Gornbein J, Abrams C, Group ftGTS. The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial. J Ocul Pharmacol Ther. 2000;16:3–18. doi:10.1089/jop.2000.16.3.
   PubMed Web of Science ®Google Scholar
• Cantor LB. The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use. Expert Opin Pharmacother. 2000;1(4):815–34. doi:10.1517/14656566.1.4.815.
   PubMedGoogle Scholar
• Schuman JS. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. Ophthalmology. 2000;107(6):1171–77. doi:10.1016/S0161-6420(00)00081-6.
   PubMed Web of Science ®Google Scholar
• Enyedi LB, Freedman SF. Safety and efficacy of brimonidine in children with glaucoma. J Am Assoc Pediatr Ophthalmol Strab. 2001;5(5):281–84. doi:10.1067/mpa.2001.117571.
   Web of Science ®Google Scholar
• Bowman RJ, Cope J, Nischal KK. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children. Eye (Lond). Jan 2004;18(1):24–26. doi:10.1038/sj.eye.6700520.
   PubMed Web of Science ®Google Scholar